retatrutide phase 2 results obesity nejm 2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide Just Broke Every Obesity

Mounjaro hits two targets

Theres also evidence suggesting that tesofensine can cure alcohol addiction via its ability to boost neurotransmitter levels: Tesofensine side effects are very uncommon and similar to other currently approved diet pills and weight loss medications

When it comes to taking GLP-1 medications for weight loss, side effects matterespecially when youre committing to a long-term plan

Experts have previously called for further research in the area

Key points: GLP-1s (glucagon-like peptide-1 receptor agonists) support type 2 diabetes by reducing appetite and supporting weight loss alongside their effects on the pancreas GLP-1-assisted programmes lead to a clinically significant weight loss of 10% or more, which can significantly reduce complications associated with obesity Combining semaglutide with lifestyle interventions leads to significantly more weight loss than lifestyle interventions alone, with 87% of participants losing more than 10% of their body weight Semaglutide is more effective at supporting weight loss than liraglutide Tirzepatide is more effective than semaglutide at reducing weight, with all three doses of tirzepatide leading to more significant weight loss than 1mg of semaglutide The higher doses of tirzepatide (10mg and 15mg) might reduce weight by 5.15kg more than 2mg of semaglutide, while there appears to be no difference between 5mg of tirzepatide and 2mg of semaglutide 3) Side effects and safety All medications have possible side effects, particularly if you live with other health conditions